Acromegaly is a chronic endocrine disorder characterized by hypersecretion of growth hormone and overproduction of insulin-like growth factor-1. Nearly all cases of acromegaly are caused by an adenoma of the anterior pituitary. A majority of patients are effectively cured by surgical intervention and those who are not receive pharmacological treatment from one of several available drug classes. The bulk of the pipeline of emerging therapies focuses on reformulating existing therapies to improve dosing frequency and route of administration.

Table of contents

  • Acromegaly - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Matthew Mackenzie

Matthew Mackenzie, M.A., is an analyst with the Infectious, Niche, and Rare Diseases Group at Decision Resources Group. Prior to joining Decision Resources Group, Matt  conducted basic science research and led clinical trials in the field of transplant immunology at Beth Israel Deaconess Medical Center/Harvard Medical School, Boston. Matt holds an M.S. in medical sciences from the Boston University School of Medicine and a B.S. in biochemistry and molecular genetics from The University of New Hampshire.